JAADRCT
Sonelokimab, a novel IL-17A- and IL-17F-inhibiting nanobody for the treatment of moderate-to-severe hidradenitis suppurativa
a global, randomized, double-blind, placebo-controlled phase 2 clinical trial (MIRA).
ConclusionSonelokimab demonstrated high levels of clinical response in patients with moderate-to-severe HS and was well tolerated.
Kimball AB, Bechara FG, … senior author Kirby BJournal of the American Academy of Dermatology